Civic Intelligence

Grace Science Foundation

990 • Fiscal year 2019 • EIN 46-5727883

Jan 01, 2019 to Dec 31, 2019 • Filed on Nov 13, 2020

Organization ProfileWWW.GRACESCIENCE.ORG
1142 Crane St 4Menlo Park, CA 94025

(415) 255-7666

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

18th percentile

0.00x

Higher debt load relative to assets than 18% of similar nonprofits.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2019

Liabilities / Revenue

17th percentile

0.00x

Higher debt load relative to revenue than 17% of similar nonprofits.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2019

Net Margin

90th percentile

46%

Higher net margin than 90% of similar nonprofits.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2019

Top Officer Pay

36th percentile

$0

Higher top officer pay than 36% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2019

Asset Growth

86th percentile

32%

Faster asset growth than 86% of similar nonprofits.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2018 to 2019

Revenue Growth

81st percentile

30%

Faster revenue growth than 81% of similar nonprofits.

2019 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2018 to 2019

Balance Sheet
Liabilities / Assets18th percentile

Assets

Up

$2,889,615

Up $693,241 (+32%) from 2018

Net Assets

Up

$2,887,414

Up $691,040 (+31%) from 2018

Liabilities

Up

$2,201

Up $2,201 from 2018

Revenue And Expenses
Liabilities / Revenue17th percentileNet Margin90th percentile

Revenue

Up

$1,561,302

Up $361,314 (+30%) from 2018

Expenses

Down

$839,395

Down $234,669 (-22%) from 2018

Net Income

Up

$721,907

Up $595,983 (+473%) from 2018

Historical Trend

Balance Sheet Trend

Asset Growth86th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$4.0M$3.0M$2.0M$1.0M$0Assets 2014: $603,778Liabilities 2014: $0Net Assets 2014: $603,7782014Assets 2015: $1,605,814Liabilities 2015: $0Net Assets 2015: $1,605,8142015Assets 2016: $1,336,131Liabilities 2016: $0Net Assets 2016: $1,336,1312016Assets 2017: $2,109,224Liabilities 2017: $16,500Net Assets 2017: $2,092,7242017Assets 2018: $2,196,374Liabilities 2018: $0Net Assets 2018: $2,196,3742018Assets 2019: $2,889,615Liabilities 2019: $2,201Net Assets 2019: $2,887,4142019Assets 2020: $2,884,506Liabilities 2020: $386Net Assets 2020: $2,884,1202020Assets 2021: $3,128,030Liabilities 2021: $29,929Net Assets 2021: $3,098,1012021Assets 2022: $3,183,591Liabilities 2022: $51,224Net Assets 2022: $3,132,3672022Assets 2023: $2,790,274Liabilities 2023: $42,997Net Assets 2023: $2,747,2772023Assets 2024: $2,224,370Liabilities 2024: $1,004Net Assets 2024: $2,223,3662024

Highlighted filing

2019

Assets$2,889,615
Liabilities$2,201
Net Assets$2,887,414
Open 2019 Filing

Operations Trend

Revenue Growth81st percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$2.0M$1.0M$0-$1.0MRevenue 2014: $664,490Expenses 2014: $60,712Net Income 2014: $603,7782014Revenue 2015: $1,560,381Expenses 2015: $558,345Net Income 2015: $1,002,0362015Revenue 2016: $600,124Expenses 2016: $869,807Net Income 2016: -$269,6832016Revenue 2017: $1,677,107Expenses 2017: $920,514Net Income 2017: $756,5932017Revenue 2018: $1,199,988Expenses 2018: $1,074,064Net Income 2018: $125,9242018Revenue 2019: $1,561,302Expenses 2019: $839,395Net Income 2019: $721,9072019Revenue 2020: $1,454,180Expenses 2020: $1,452,901Net Income 2020: $1,2792020Revenue 2021: $1,327,113Expenses 2021: $1,113,132Net Income 2021: $213,9812021Revenue 2022: $1,236,228Expenses 2022: $1,218,482Net Income 2022: $17,7462022Revenue 2023: $826,626Expenses 2023: $1,289,174Net Income 2023: -$462,5482023Revenue 2024: $943,011Expenses 2024: $1,519,386Net Income 2024: -$576,3752024

Highlighted filing

2019

Revenue$1,561,302
Expenses$839,395
Net Income$721,907
Open 2019 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2019 to Dec 31, 2019
Signed
Nov 13, 2020
Return Version
2019v5.1
Gross Receipts
$1,565,376
Mission and Program Overview

Mission

The mission of the foundation is to support and fund the development of life-saving treatment for patients that are deficient in the n-glycanese enzyme and those suffering from related genetic diseases. The activities of the foundation will involve providing grant funding to hospitals and medical research facilities which are conducting medical research in various fields relating to the search for understanding and treatment of this condition, and fostering collaboration between academia, research institutions, hospitals, private companies, and governmental agencies.

The mission of the foundation is to support and fund the development of life-saving treatment for patients that are deficient in the n-glycanese enzyme and those suffering from related genetic diseases.

Balance Sheet Detail
LineBeginningEndChange
Assets
Rtn Earn Endowment Incm Other Fnds$2,196,374$2,887,414▲ $691,040
Cash and Non-Interest-Bearing Accounts$2,192,300$2,885,541▲ $693,241
Investments in Publicly Traded Securities$4,074$4,074→ $0
Pd in Cap Srpls Land Bldg Eqp Fund$0$0→ $0
Cap Stk Tr Prin Current Funds$0$0→ $0
Total Assets$2,196,374$2,889,615▲ $693,241
Liabilities
Accounts Payable and Accrued Expenses-$2,201-
Total Liabilities$0$2,201▲ $2,201
Net Assets / Fund Balance
Total Net Assets Fund Balance$2,196,374$2,887,414▲ $691,040
Total Liabilities and Net Assets / Fund Balance$2,196,374$2,889,615▲ $693,241
Compensation and Service Providers
Top Officer Pay36th percentile

Board Members and Trustees

NameTitle
Matthew WilseyPresident
Chelsea ClintonDirector
Elle StephensDirector
J Taylor CrandallDirector
Pete BrigerDirector
Egon DurbanChief Financial Officer
Ken DrazanSecretary
Revenue and Support

Revenue Composition

Contributions and Grants
$1,522,789
Program Service Revenue
$0
Investment Income
$38,513
Other Revenue
$0
All Other Contributions
$1,522,789
Change in Net Assets
$721,907

Noncash Contribution Practices

Property subject to holding requirements
No
Reviewed unusual noncash gifts
No
Third parties used for noncash contributions
No

Noncash Contributions

Contribution TypeContribution CountReported AmountValuation Method
Securities Publicly Traded3$480,354Fair Market Value
Total Noncash Contributions3$480,354-
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$709,424
Other Expenses$129,971
Professional Fundraising Fees$0
Salaries, Compensation, and Employee Benefits$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Grants to Domestic Orgs$653,174--$653,174
Fees for Services Other-$68,750-$68,750
Foreign Grants$56,250--$56,250
Travel$26,934--$26,934
Fees for Services Legal-$13,368-$13,368
Advertising-$7,244-$7,244
Fees for Services Accounting-$4,250-$4,250
Office Expenses$1,637--$1,637
Conferences and Meetings-$1,119-$1,119
Insurance-$955-$955
Other Expenses-$160-$160
Total Functional Expenses$737,995$101,400$0$839,395
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
The Jackson LaboratoryBar Harbor, ME501(c)(6)Ngly1 Work With Cat Lutz$167,533
Salk Institute for Biological StudiesLa Jolla, CA501(c)(3)Ngly1 Work in Gage Lab$124,216
Stanford UniversityPalo Alto, CA501(c)(3)Ngly1 Work in Bertozzi/snyder/steinmetz Labs & Natural History Protocol Development$106,792
University of Texas Southwestern Medical CenterDallas, TX501(c)(3)Ngly1 Work in Yan Lab$71,740
Virginia Commonwealth UniversityRichmond, VA501(c)(3)Ngly1 Work in Radhakrishnan Lab$58,000
Massachusetts General HospitalBoston, MA501(c)(3)Nygly1 Work in Rukvun Lab$57,000
University of Massachusetts Medical SchoolWorcester, MA501(c)(6)Ngly1 Work in Gao Lab$30,000
New York Stem Cell FoundationNew York, NY-Ngly1 Stem Cell Lines$21,250
Charles River LaboratoriesWilmington, MA-Ngly1 Rat Model$14,560
BioivtWestbury, NY501(c)(3)Comparing Cerebrospinal Fluid Control Samples$2,083

International Summary

Offices
0
Employees
0
Spending
$0

International Compliance

Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
No
Business relationship with 35% controlled entity
No
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
No
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 2

“The president of the foundation has immaterial ownership interest, in the investments of fortress and silver lake, which are managed by two of the directors.”

Form 990, Part VI, Section A, Line 7A

“The president of the foundation has authority to elect one or more members of the governing body.”

Form 990, Part VI, Section A, Line 8A

“The governing body of the foundation did not meet during the year.”

Form 990, Part VI, Section A, Line 8B

“The foundation does not have any committees.”

Form 990, Part VI, Section B, Line 11B

“Prior to filing from 990, the foundation's president will review the form.”

Form 990, Part VI, Section C, Line 18

“AVAILABLE UPON REQUEST.”

Form 990, Part VI, Section C, Line 19

“AVAILABLE UPON REQUEST.”

Filing and Contact Details

Filer

Filer Name
Grace Science Foundation
EIN
46-5727883
Phone
4152557666
Address
1142 CRANE ST 4, MENLO PARK, CA 94025

Signing Officer

Name
Matthew R Wilsey
Title
President
Phone
4152557666
Signed
2020-11-13
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Matthew R Wilsey
Formed
2014
Legal Domicile
CA
Voting Board Members
7
Independent Board Members
7
Employees
0
Volunteers
0

Preparer

Firm
Oum & Co Llp
Address
601 CALIFORNIA STREET SUITE 1800, SAN FRANCISCO, CA 94108
Preparer
Bradford Weisert
Phone
4154343744
Raw XML AppendixShowing 400 of 502 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt02201
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES.
IRS990/AddressChangeInd0X
IRS990/AdvertisingGrp/ManagementAndGeneralAmt07244
IRS990/AdvertisingGrp/TotalAmt07244
IRS990/AllOtherContributionsAmt01522789
IRS990/AnnualDisclosureCoveredPrsnInd00
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0GRACE SCIENCE FOUNDATION
IRS990/BooksInCareOfDetail/PhoneNum04152557666
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt01142 CRANE ST 4
IRS990/BooksInCareOfDetail/USAddress/CityNm0MENLO PARK
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd094025
IRS990/BusinessRlnWith35CtrlEntInd00
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CapStkTrPrinCurrentFundsGrp/BOYAmt00
IRS990/CapStkTrPrinCurrentFundsGrp/EOYAmt00
IRS990/CashNonInterestBearingGrp/BOYAmt02192300
IRS990/CashNonInterestBearingGrp/EOYAmt02885541
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd00
IRS990/CompensationProcessOtherInd00
IRS990/ConferencesMeetingsGrp/ManagementAndGeneralAmt01119
IRS990/ConferencesMeetingsGrp/TotalAmt01119
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt01522789
IRS990/CYGrantsAndSimilarPaidAmt0709424
IRS990/CYInvestmentIncomeAmt038513
IRS990/CYOtherExpensesAmt0129971
IRS990/CYOtherRevenueAmt00
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt0721907
IRS990/CYSalariesCompEmpBnftPaidAmt00
IRS990/CYTotalExpensesAmt0839395
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt01561302
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd01
IRS990/DelegationOfMgmtDutiesInd00
IRS990/Desc0THE JACKSON LABORATORY (CAT LUTZ) - THE TEAM GENERATED A SPECIFIC MOUSE MODEL OF NGLY1 LOSS AND COMPLETED A DEEP PHENOTYPIC ANALYSIS OF THESE MICE TO CHARACTERIZE DISEASE RELEVANT PHENOTYPES AND MAP THEIR APPEARANCE OVER TIME. THESE STUDIES PROVIDED INSIGHTS INTO WHICH TISSUES ARE IMPORTANT IN DISEASE PATHOLOGY AND PROVIDE A MODEL FOR TESTING POTENTIAL THERAPIES TO REVERSE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd00
IRS990/DonorAdvisedFundInd00
IRS990/DonorRstrOrQuasiEndowmentsInd00
IRS990/ElectionOfBoardMembersInd01
IRS990/EmployeeCnt00
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt0172296
IRS990/FamilyOrBusinessRlnInd01
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt04250
IRS990/FeesForServicesAccountingGrp/TotalAmt04250
IRS990/FeesForServicesLegalGrp/ManagementAndGeneralAmt013368
IRS990/FeesForServicesLegalGrp/TotalAmt013368
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt068750
IRS990/FeesForServicesOtherGrp/TotalAmt068750
IRS990/ForeignActivitiesInd00
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt056250
IRS990/ForeignGrantsGrp/TotalAmt056250
IRS990/ForeignOfficeInd00
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt020.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt51.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt61.00
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/PersonNm0MATTHEW WILSEY
IRS990/Form990PartVIISectionAGrp/PersonNm1EGON DURBAN
IRS990/Form990PartVIISectionAGrp/PersonNm2KEN DRAZAN
IRS990/Form990PartVIISectionAGrp/PersonNm3PETE BRIGER
IRS990/Form990PartVIISectionAGrp/PersonNm4CHELSEA CLINTON
IRS990/Form990PartVIISectionAGrp/PersonNm5J TAYLOR CRANDALL
IRS990/Form990PartVIISectionAGrp/PersonNm6ELLE STEPHENS
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/TitleTxt0PRESIDENT
IRS990/Form990PartVIISectionAGrp/TitleTxt1CHIEF FINANCIAL OFFICER
IRS990/Form990PartVIISectionAGrp/TitleTxt2SECRETARY
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990ProvidedToGvrnBodyInd00
IRS990/FormationYr02014
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedInd00
IRS990/FundraisingActivitiesInd00
IRS990/GainOrLossGrp/SecuritiesAmt017932
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt07
IRS990/GrantAmt0167534
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt0653174
IRS990/GrantsToDomesticOrgsGrp/TotalAmt0653174
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossAmountSalesAssetsGrp/SecuritiesAmt022006
IRS990/GrossReceiptsAmt01565376
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd00
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt07
IRS990/IndivRcvdGreaterThan100KCnt00
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InsuranceGrp/ManagementAndGeneralAmt0955
IRS990/InsuranceGrp/TotalAmt0955
IRS990/InvestmentIncomeGrp/ExclusionAmt020581
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt020581
IRS990/InvestmentInJointVentureInd00
IRS990/InvestmentsPubTradedSecGrp/BOYAmt04074
IRS990/InvestmentsPubTradedSecGrp/EOYAmt04074
IRS990/IRPDocumentCnt04
IRS990/IRPDocumentW2GCnt00
IRS990/LegalDomicileStateCd0CA
IRS990/LessCostOthBasisSalesExpnssGrp/SecuritiesAmt04074
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingCashInd0X
IRS990/MinutesOfCommitteesInd00
IRS990/MinutesOfGoverningBodyInd00
IRS990/MissionDesc0THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESEARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTANDING AND TREATMENT OF THIS CONDITION, AND FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt02196374
IRS990/NetAssetsOrFundBalancesEOYAmt02887414
IRS990/NetGainOrLossInvestmentsGrp/ExclusionAmt017932
IRS990/NetGainOrLossInvestmentsGrp/TotalRevenueColumnAmt017932
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt0-30867
IRS990/NoListedPersonsCompensatedInd0X
IRS990/NoncashContributionsAmt0480354
IRS990/NondeductibleContributionsInd00
IRS990/OfficeExpensesGrp/ProgramServicesAmt01637
IRS990/OfficeExpensesGrp/TotalAmt01637
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrgDoesNotFollowFASB117Ind0X
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherExpensesGrp/Desc0SHIPPING FEES
IRS990/OtherExpensesGrp/Desc1BRANDING/LOGO/VIDEO/WEB
IRS990/OtherExpensesGrp/Desc2OTHER FEES (BANK, CREDI
IRS990/OtherExpensesGrp/Desc3FILING FEES
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt02751
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt11424
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt21379
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt3160
IRS990/OtherExpensesGrp/TotalAmt02751
IRS990/OtherExpensesGrp/TotalAmt11424
IRS990/OtherExpensesGrp/TotalAmt21379
IRS990/OtherExpensesGrp/TotalAmt3160
IRS990/OtherWebsiteInd0X
IRS990/PartialLiquidationInd00
IRS990/PdInCapSrplsLandBldgEqpFundGrp/BOYAmt00
IRS990/PdInCapSrplsLandBldgEqpFundGrp/EOYAmt00
IRS990/PoliticalCampaignActyInd00
IRS990/PrincipalOfficerNm0MATTHEW R WILSEY
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0SALK INSTITUTE FOR BIOLOICAL SCIENCES (GAGE LAB)- TEAM HAS BEEN DEVELOPING INDUCED PLURIPOTENT STEM CELLS (IPSCS) FROM NGLY1 DEFICIENT PATIENTS AS A MODEL SYSTEM TO CHARACTERIZE THE FUNCTIONAL CHANGES CAUSED BY NGLY1 LOSS AND TO TEST CANDIDATE THERAPIES TO REVERSE THOSE CHANGES. THEY OBSERVED THE PRESENCE OF PROTEIN AGGREGATES, MITOCHONDIAL DYSFUNCTION AND REDUCED SYNAPTIC ACTIVITY IN NEURONS DERIVED FROM PATIENT IPSCS COMPARED WITH CONTROLS. THE TEAM HAS VERIFIED THAT THESE PHENOTYPIC CHANGES ARE RESUCED BY REINTRODUCING A FUNCTIONAL NGLY1 GENE INTO THE CELLS, AND HAS BEEN CHARACTERIZING THE COMPOSITION OF THE AGGREGATES FOUND IN NGLY1 CELLS. THESE DISCOVERIES IDENTIFIED PHENOTYPES THAT CAN BE LEVERAGED FOR HIGH-THROUGHPUT DRUG SCREENS AND PROVIDE INSIGHT AS TO THE CELL TYPES AFFECTED BY THE DISEASE IN PATIENTS.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0128978
IRS990/ProgSrvcAccomActy2Grp/GrantAmt0124216
IRS990/ProgSrvcAccomActy3Grp/Desc0UNIVERSITY OF TEXAS SOUTHWESTERN (YAN LAB) - TEAM HAS BEEN GENERATING AND CHARACTERIZING SEVERAL MOUSE MODELS OF NGLY1 DEFICIENCY, INCLUDING MODELS IN WHICH THE GENE IS INACTIVATED IN CERTAIN TISSUES AND CONDITIONALLY AFTER BIRTH.THIS HAS ALLOWED THEM TO USE THESE MOUSE MODELS TO CHARACTERIZE NEUROLOGICAL PHENOTYPES, NEUROPATHOLOGICAL CHANGES, INFLAMMATION, SENSORY AND MOTOR DEFECTS, AND DISEASE ASSOCIATED BIOMARKERS. THESE ANIMAL MODELS PROVIDE INSIGHTS INTO THE SPECIFIC DEFECTS THAT RESULT FROM NGLY1 LOSS AND ESTABLISH A FOUNDATION TO TEST CANDIDATE THERAPIES INCLUDING GENE THERAPIES AND SMALL MOLECULE DRUGS. THE TEAM HAS ALSO FOUND THAT NGLY1 DEFICIENCY TRIGGERS A SPECIFIC INNATE IMMUNE PATHWAY MEDIATED BY THE CGAS/STING PATHWAY. THEY HAVE DEVELOPED TOOLS TO DETERMINE WHETHER ACTIVATED STING SIGNALLING CONTRIBUTES TO THE PATHOLOGY ASSOCIATED WITH NGLY1 DEFICIENCY AND WHETHER BLOCKING THIS PATHWAY PROVIDES THERAPEUTIC BENEFIT.
IRS990/ProgSrvcAccomActy3Grp/ExpenseAmt076502
IRS990/ProgSrvcAccomActy3Grp/GrantAmt071740
IRS990/ProgSrvcAccomActyOtherGrp/Desc0MASSACHUSETTS GENERAL HOSPITAL (RUVKUN LAB) - TEAM CONTINUED THEIR ANALYSIS OF THE GENETIC MODIFIERS OF PROTEASOME DYSFUNCTION THEY PREVIOUSLY IDENTIFIED IN PNG-1 / NGLY1 DEFICIENT C. ELEGANS. THIS LED TO THE IDENTIFICATION OF SEVERAL PATHWAYS WHOSE DISRUPTION APPEARS BENEFICIAL TO PROTEASOME DYSFUNCTION IN NGLY1 DEFICIENT ANIMALS, A FINDING THAT COULD TRANSLATE INTO A POTENTIAL THERAPY FOR THE DISEASE IN HUMANS. THEY ALSO DEMONSTRATED NGLY1 HAS A CRITICAL FUNCTION TO EDIT THE PROTEIN SEQUENCE OF ONE OF ITS KEY SUBSTRATES, THE TRANSCRIPTIONAL REGULATOR SKN-1A / NFE2L1, AND THEREBY REGULATE ITS FUNCTION TO MAINTAIN PROTEIN HOMEOSTASIS IN THE CELL. ADDITIONALLY, THE TEAM DEMONSTRATED THAT SKN-1A / NFE2L1 IS ACTIVATED BY MISFOLDED PROTEINS, A FINDING WITH POTENTIAL RELEVANCE TO NEURODEGENERATIVE DISEASES. COLLECTIVELY, THESE RESULTS LED TO TWO PUBLICATIONS IN INFLUENTIAL JOURNALS.
IRS990/ProgSrvcAccomActyOtherGrp/Desc1STANFORD UNIVERSITY (BERTOZZI LAB) - TEAM CONTINUED INVESTIGATIONS ON THE ROLE OF FERROPTOSIS AND OXIDATIVE STRESS IN THE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY. THESE FINDINGS TOUCH ON KNOWN PATHWAYS AND COULD THEREFORE INFORM POTENTIAL THERAPEUTIC STRATEGIES. ADDITIONALLY, THE TEAM HAS BEEN IDENTIFIYING AND STUDYING NGLY1 INTERACTORS AND POTENTIAL SUBSTRATES. THIS IS CRITICAL TO UNCOVERING PROTEINS INVOLVED IN NGLY1 FUNCTION AS WELL AS ADDITIONAL PROTEINS, LIKE NFE2L1, THAT NGLY1 MAY REGULATE THROUGH DEGLYCOSYLATION. SUCH PROTEINS COULD SERVE AS POTENTIAL TARGETS FOR A SMALL COMPOUND THERAPEUTIC AND COULD PROVIDE ESSENTIAL INSIGHT INTO NGLY1 BIOLOGY.
IRS990/ProgSrvcAccomActyOtherGrp/Desc2STANFORD UNIVERSITY NGLY1 NATURAL HISTORY STUDY (MAURA RUZHNIKOV) - TEAM INITIATED A NATURAL HISTORY STUDY TO DEFINE THE CLINICAL SPECTRUM OF THE DISEASE AND ITS PROGRESSION, AND DEFINE BIOMARKER ENDPOINTS FOR USE IN THERAPEUTIC TRIALS. THIS STUDY IS LED BY DR. MAURA RUZHNIKOV, MD, A CHILD NEUROLOGIST AND MEDICAL GENETICIST FOCUSING ON THE DIAGNOSIS AND MANAGEMENT OF RARE NEUROLOGIC DISORDERS, INCLUDING GENETIC EPILEPSY SYNDROMES, CHILDHOOD NEURODEGENERATIVE DISEASES AND UNDIAGNOSED SUSPECTED GENETIC CONDITIONS. TEAM HAS DEVELOPED AND RECEIVED APPROVAL FOR THE STUDY DESIGN, RECRUITED PARTICIPANTS, AND BEGUN GATHERING CLINICAL DATA IN THE FIRST PATIENT VISITS. ULTIMATELY, THE STUDY WILL ENROLL MORE THAN TWENTY-FIVE PATEINTS AND FOLLOW THEM LONGITUDINALLY OVER FIVE YEARS.
IRS990/ProgSrvcAccomActyOtherGrp/Desc3OTHER PROGRAM SERVICES ARE RELATED TO RESEARCH AND DEVELOPMENT TO UNDERSTAND AND CURE CARE DISEASES BEGINNING WITH NGLY1 DEFICIENCY.
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt061762
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt144497
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt271818
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt3182142
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt057000
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt139735
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt267057
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt3182142
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt01187802
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt0898851
IRS990/PYInvestmentIncomeAmt012186
IRS990/PYOtherExpensesAmt0175213
IRS990/PYOtherRevenueAmt00
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt0125924
IRS990/PYSalariesCompEmpBnftPaidAmt00
IRS990/PYTotalExpensesAmt01074064
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt01199988
IRS990/QuidProQuoContributionsInd00
IRS990/ReconcilationRevenueExpnssAmt0721907
IRS990/RegularMonitoringEnfrcInd00
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd00
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/RtnEarnEndowmentIncmOthFndsGrp/BOYAmt02196374
IRS990/RtnEarnEndowmentIncmOthFndsGrp/EOYAmt02887414
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt01522789
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt01157365
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt01677107
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt0600124
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt01560381
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt06517766
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.62200
IRS990ScheduleA/PublicSupportTotal170Amt04053937
IRS990ScheduleA/SubstantialContributorsTotAmt02463829
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt01522789
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt01157365
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt01677107
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt0600124
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt01560381
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt06517766
IRS990ScheduleA/TotalSupportAmt06517766
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990/ScheduleBRequiredInd01
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinuationTotalEmployeeCnt00
IRS990ScheduleF/ContinuationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt056250
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0CHECK
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0NGYL1 WORK IN MOFFAT'S LABS AT UNIVERSITY OF TORONTO
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0CANADA
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt00
IRS990ScheduleF/SubtotalOfficesCnt00
IRS990ScheduleF/SubtotalSpentAmt00
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0PART III ACCOUNTING METHOD:
IRS990ScheduleF/TotalEmployeeCnt00
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalSpentAmt00
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt02083
IRS990ScheduleI/RecipientTable/CashGrantAmt1106792
IRS990ScheduleI/RecipientTable/CashGrantAmt257000
IRS990ScheduleI/RecipientTable/CashGrantAmt358000
IRS990ScheduleI/RecipientTable/CashGrantAmt4124216
IRS990ScheduleI/RecipientTable/CashGrantAmt5167533
IRS990ScheduleI/RecipientTable/CashGrantAmt630000
IRS990ScheduleI/RecipientTable/CashGrantAmt771740
IRS990ScheduleI/RecipientTable/CashGrantAmt814560
IRS990ScheduleI/RecipientTable/CashGrantAmt921250
IRS990ScheduleI/RecipientTable/IRCSectionDesc0501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc1501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc2501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc3501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc4501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc5501(C)(6)
IRS990ScheduleI/RecipientTable/IRCSectionDesc6501(C)(6)
IRS990ScheduleI/RecipientTable/IRCSectionDesc7501(C)(3)
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0COMPARING CEREBROSPINAL FLUID CONTROL SAMPLES
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt1NGLY1 WORK IN BERTOZZI/SNYDER/STEINMETZ LABS & NATURAL HISTORY PROTOCOL DEVELOPMENT
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt2NYGLY1 WORK IN RUKVUN LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt3NGLY1 WORK IN RADHAKRISHNAN LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt4NGLY1 WORK IN GAGE LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt5NGLY1 WORK WITH CAT LUTZ
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt6NGLY1 WORK IN GAO LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt7NGLY1 WORK IN YAN LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt8NGLY1 RAT MODEL
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt9NGLY1 STEM CELL LINES
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0BIOIVT
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt1STANFORD UNIVERSITY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt2MASSACHUSETTS GENERAL HOSPITAL
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt3VIRGINIA COMMONWEALTH UNIVERSITY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt4SALK INSTITUTE FOR BIOLOGICAL STUDIES
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt5THE JACKSON LABORATORY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt6UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt7UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt8CHARLES RIVER LABORATORIES
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt9NEW YORK STEM CELL FOUNDATION
IRS990ScheduleI/RecipientTable/RecipientEIN0941156365
IRS990ScheduleI/RecipientTable/RecipientEIN1041564655
IRS990ScheduleI/RecipientTable/RecipientEIN2546001758
IRS990ScheduleI/RecipientTable/RecipientEIN3952160097
IRS990ScheduleI/RecipientTable/RecipientEIN4010211513
IRS990ScheduleI/RecipientTable/RecipientEIN5043167352
IRS990ScheduleI/RecipientTable/RecipientEIN6756002868
IRS990ScheduleI/RecipientTable/RecipientEIN7202905531
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt0123 FROST ST
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt13145 PORTER DRIVE
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt232 FRUIT ST
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt31201 E MARSHALL ST 4-100
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt410010 N TORREY PINES ROAD
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt5600 MAIN STREET
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt655 LAKE AVENUE NORTH
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt75323 HARRY HINES BLVD
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt8251 BALLARDVALE ST
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt9619 W 54TH STREET
IRS990ScheduleI/RecipientTable/USAddress/CityNm0WESTBURY
IRS990ScheduleI/RecipientTable/USAddress/CityNm1PALO ALTO
IRS990ScheduleI/RecipientTable/USAddress/CityNm2BOSTON
IRS990ScheduleI/RecipientTable/USAddress/CityNm3RICHMOND
IRS990ScheduleI/RecipientTable/USAddress/CityNm4LA JOLLA
IRS990ScheduleI/RecipientTable/USAddress/CityNm5BAR HARBOR
IRS990ScheduleI/RecipientTable/USAddress/CityNm6WORCESTER
IRS990ScheduleI/RecipientTable/USAddress/CityNm7DALLAS
IRS990ScheduleI/RecipientTable/USAddress/CityNm8WILMINGTON
IRS990ScheduleI/RecipientTable/USAddress/CityNm9NEW YORK
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd0NY
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd1CA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd2MA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd3VA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd4CA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd5ME
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd6MA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd7TX
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd8MA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd9NY
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd011590
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd194304
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd202114
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd323298
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd492037
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd504609
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd601655
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd775390
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd801887
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd910019
IRS990ScheduleI/SupplementalInformationDetail/ExplanationTxt0* BEFORE FUNDING A PRINCIPAL INVESTIGATOR, THE FOUNDATION REQUIRES A DETAILED PROPOSAL WITH OBJECTIVES AND MILESTONES * THE PROPOSALS ARE REVIEWED BY THE FOUNDATION AND SCIENTIFIC ADVISORY BOARD * THE PROPOSALS ARE OFTEN REVISED SEVERAL TIMES TO GET THE CORRECT FIT * ONCE FUNDED, EACH PRINCIPAL INVESTIGATOR SUBMITS A WRITTEN SUMMARY EVERY QUARTER * THIS UPDATE IS TWO TO THREE PAGES IN LENGTH * THE REPORTS DISCUSS PROGRESS, HIGHLIGHT ROADBLOCKS AND IDENTIFY WHERE THEY NEED HELP * THE FOUNDATION STEPS-IN WHERE APPROPRIATE TO MAKE SURE OBJECTIVES AND MILESTONES ARE MET * IN ADDITION TO QUARTERLY REPORTS, THE FOUNDATION HOLDS A MONTHLY CONFERENCE CALL WHERE TWO TO THREE PRINCIPAL INVESTIGATORS PRESENT THEIR LATEST WORK * BEYOND THE ABOVE TWO INITIATIVES, THE FOUNDATION HOLDS ONE TO TWO IN-PERSON MEETINGS PER YEAR * DR. KEVIN LEE (CHIEF SCIENTIFIC OFFICER), DR. SELINA DWIGHT (PROGRAM MANAGER), AND MATT WILSEY(PRESIDENT) CONTACT RESEARCHERS AND PRINCIPAL INVESTIGATORS ON A REGULAR BASIS VIA EMAIL, PHONE, OR ONE ON ONE MEETINGS THE PRESIDENT ENSURES THAT EVERY DOLLAR IS USED TO SUPPORT THE GRACE SCIENCE FOUNDATION'S MISSION.
IRS990ScheduleI/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleI/Total501c3OrgCnt08
IRS990ScheduleI/TotalOtherOrgCnt02
IRS990/ScheduleJRequiredInd00
IRS990ScheduleM/AnyPropertyThatMustBeHeldInd00
IRS990ScheduleM/ReviewProcessUnusualNCGiftsInd00
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/ContributionCnt03
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/MethodOfDeterminingRevenuesTxt0FAIR MARKET VALUE
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/NonCashCheckboxInd0X
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/NoncashContributionsRptF990Amt0480354
IRS990ScheduleM/ThirdPartiesUsedInd00
IRS990/ScheduleORequiredInd01
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0THE PRESIDENT OF THE FOUNDATION HAS IMMATERIAL OWNERSHIP INTEREST, IN THE INVESTMENTS OF FORTRESS AND SILVER LAKE, WHICH ARE MANAGED BY TWO OF THE DIRECTORS.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2019 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$2,889,615
Liabilities
$2,201
Net assets
$2,887,414
Revenue
$1,561,302
Expenses
$839,395
Net income
$721,907
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$2.22$0.00$2.22$0.94$1.52$0.58
2023Detailed filing. Detailed filing data is available for this year.$2.79$0.04$2.75$0.83$1.29$0.46
2022Facts available. Structured filing facts are available, but richer extracted sections are limited.$3.18$0.05$3.13$1.24$1.22$0.02
2021Detailed filing. Detailed filing data is available for this year.$3.13$0.03$3.10$1.33$1.11$0.21
2020Detailed filing. Detailed filing data is available for this year.$2.88$0.00$2.88$1.45$1.45$0.00
2019Detailed filing. Detailed filing data is available for this year.$2.89$0.00$2.89$1.56$0.84$0.72
2018Detailed filing. Detailed filing data is available for this year.$2.20$0.00$2.20$1.20$1.07$0.13
2017Detailed filing. Detailed filing data is available for this year.$2.11$0.02$2.09$1.68$0.92$0.76
2016Detailed filing. Detailed filing data is available for this year.$1.34$0.00$1.34$0.60$0.87$0.27
2015Summary only. Only limited summary data is available for this year.$1.61$0.00$1.61$1.56$0.56$1.00
2014Detailed filing. Detailed filing data is available for this year.$0.60$0.00$0.60$0.66$0.06$0.60